BNGOW (Bionano Genomics) EBIT: $-30.40 Mil (TTM As of Mar. 2026)

What is Bionano Genomics EBIT?

Bionano Genomics BNGOW 64 EBIT is $-30.40 Mil as of Mar. 2026. GuruFocus rates BNGOW with a GF Score™ of 64/100. The stock has 3 warning signs investors should review.

Bionano Genomics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-8.22 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-30.40 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bionano Genomics's annualized ROC % for the quarter that ended in Mar. 2026 was -68.85%. Bionano Genomics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -109.98%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Bionano Genomics (NAS:BNGOW) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bionano Genomics's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-31.588 * ( 1 - 0% )	/	( (47.363	+	44.399)	/ 2 )
=	-31.588	/	45.881
=	-68.85 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	73.584	-	6.952	-	( 19.269	-	max(0, 22.942	-	45.386	+	19.269	))
=	47.363

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	64.804	-	6	-	( 14.405	-	max(0, 21.228	-	38.975	+	14.405	))
=	44.399

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Bionano Genomics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-32.884	/	( ( (21.159 + max(4.109, 0))	+	(20.146 + max(14.386, 0)) )	/	2 )
=	-32.884	/	( ( 25.268	+	34.532 )	/	2 )
=	-32.884	/	29.9
=	-109.98 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(5.2	+	5.448	+	15.457)	-	(6.952	+	0.967	+	14.077)
=	4.109

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(4.133	+	5.307	+	15.13)	-	(6	+	1.126	+	3.058)
=	14.386

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bionano Genomics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-30.397	/	0.000
	=	%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionano Genomics EBIT Related Terms

Bionano Genomics EBIT Historical Data

* Premium members only.

The historical data trend for Bionano Genomics's EBIT can be seen below:

Bionano Genomics EBIT Chart

Bionano Genomics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-77.23

-130.41

-235.43

-109.61

-26.03

Bionano Genomics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-3.01	-6.19	-8.16	-7.83	-8.22

BNGOW vs UEEC, ZJYL, RGNT: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Bionano Genomics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bionano Genomics EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bionano Genomics's EV-to-EBIT falls into.

Save Embed

64GF Score

Bionano Genomics Inc BNGOW

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Bionano Genomics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-30.40 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-30.40 Mil mean?

Bionano Genomics (BNGOW) has a EBIT of $-30.40 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bionano Genomics.

Is Bionano Genomics' EBIT too high?

Bionano Genomics' current EBIT is $-30.40 Mil. Overall, Bionano Genomics has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.

How does Bionano Genomics' EBIT compare to UEEC and ZJYL?

Bionano Genomics' EBIT of $-30.40 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Medical Devices & Instruments company?

A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bionano Genomics. Bionano Genomics's current EBIT is $-30.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Bionano Genomics stock overvalued right now?

Bionano Genomics (BNGOW) has a current EBIT of $-30.40 Mil. The current EBIT is $-30.40 Mil. Bionano Genomics' overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Bionano Genomics (BNGOW), the current EBIT is $-30.40 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bionano Genomics Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies UEEC ZJYL RGNT RVP MHUAF LUCY CUPR NXGL CBSC FEMY ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST TSE:4543 XPAR:DIM

Other Exchanges BNGO:USA BNGO:Mexico

Address 9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121

Website https://www.bionano.com

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.

64GF Score

Get the complete analysis for BNGOW

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00

Price

View BNGOW Analysis

See EBIT data for all stocks →